Enhanced Group Launches AI-Powered Enhanced OS
New York, August 18, 2026 Enhanced Group, Inc. (NYSE: ENHA) has announced Enhanced OS, an AI-powered platform designed to...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
New York, August 18, 2026 Enhanced Group, Inc. (NYSE: ENHA) has announced Enhanced OS, an AI-powered platform designed to...
Ingelheim, Germany, August,11, 2026 Boehringer Ingelheim has acquired Evax AG, a Swiss biotechnology company focused on equine health, expanding...
Amsterdam, the Netherlands, August,11, 2026 Royal Philips and Exor N.V. have agreed to update their long-term relationship agreement, reinforcing...
October 14, 2025 | Dallas, TX & Aurora, CO — Verily, UCHealth, the University of Colorado Anschutz, and RefinedScience...
